

Brief report

Mutations of the *SF3B1* splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

*Davide Rossi,¹ *Alessio Bruscatto,¹ Valeria Spina,¹ Silvia Rasi,¹ Hossein Khiabani,² Monica Messina,³ Marco Fangazio,¹ Tiziana Vaisitti,⁴ Sara Monti,¹ Sabina Chiaretti,⁵ Anna Guarini,⁵ Ilaria Del Giudice,⁵ Michaela Cerri,¹ Stefania Cresta,¹ Clara Deambrogi,¹ Ernesto Gargiulo,¹ Valter Gattei,⁶ Francesco Forconi,⁷ Francesco Bertoni,⁸ Silvia Deaglio,⁴ Raul Rabadan,² Laura Pasqualucci,^{3,9,10} †Robin Foà,^{5,11} †Riccardo Dalla-Favera,^{3,9,12,13} and †Gianluca Gaidano¹

¹Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; ²Department of Biomedical Informatics and Center for Computational Biology and Bioinformatics and ³Institute for Cancer Genetics and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY; ⁴Department of Genetics, Biology and Biochemistry and Human Genetics Foundation, University of Turin, Turin, Italy; ⁵Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy; ⁶Clinical and Experimental Onco-Hematology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy; ⁷Division of Hematology, University of Siena, Siena, Italy; ⁸Oncology Institute of Southern Switzerland–Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; ⁹Department of Pathology & Cell Biology, Columbia University, New York, NY; ¹⁰Institute of Hematology, University of Perugia, Perugia, Italy; ¹¹Fondazione Eleonora Lorillard Spencer Cenci, Sapienza University, Rome, Italy; and Departments of ¹²Genetics and Development and ¹³Microbiology and Immunology, Columbia University, New York, NY

The genetic lesions identified in chronic lymphocytic leukemia (CLL) do not entirely recapitulate the disease pathogenesis and the development of serious complications, such as chemorefractoriness. While investigating the coding genome of fludarabine-refractory CLL, we observed that mutations of *SF3B1*, encoding a splicing factor and representing a critical component of the cell spliceosome, were re-

current in 10 of 59 (17%) fludarabine-refractory cases, with a frequency significantly greater than that observed in a consecutive CLL cohort sampled at diagnosis (17/301, 5%; $P = .002$). Mutations were somatically acquired, were generally represented by missense nucleotide changes, clustered in selected HEAT repeats of the *SF3B1* protein, recurrently targeted 3 hotspots (codons 662, 666, and

700), and were predictive of a poor prognosis. In fludarabine-refractory CLL, *SF3B1* mutations and *TP53* disruption distributed in a mutually exclusive fashion ($P = .046$). The identification of *SF3B1* mutations points to splicing regulation as a novel pathogenetic mechanism of potential clinical relevance in CLL. (*Blood*. 2011; 118(26):6904-6908)

Introduction

The clinical course of chronic lymphocytic leukemia (CLL) ranges from a very indolent disorder with a normal lifespan for the patient to a rapidly progressive disease that leads to death. Occasionally, CLL undergoes a transformation to Richter syndrome (RS).¹⁻³ The variable clinical course of CLL is driven, at least in part, by the disease's immunogenetic and molecular heterogeneity.⁴

Despite recent advances, the genetic lesions identified to date do not fully recapitulate the molecular pathogenesis of CLL and do not entirely explain the development of severe complications, such as chemorefractoriness, which still represent unmet clinical needs.⁵ In approximately 40% of cases, refractoriness to fludarabine is attributable to the disruption of *TP53*, but in a sizeable fraction of patients, the molecular basis of this aggressive phenotype remains unclear.⁶

Recently, 2 independent studies of the CLL coding genome investigated at disease presentation have revealed a restricted number of mutated genes, including *NOTCH1*.^{7,8} These studies have provided a proof of concept that, similar to other malignancies, genome-wide mutational analysis might identify novel lesions

of biologic and clinical relevance in CLL. On these grounds, we have embarked on the investigation of the coding genome of fludarabine-refractory CLL to identify genetic lesions associated with chemorefractoriness. The initial phases of this analysis have revealed recurrent mutations of *SF3B1*, a critical component of the cell spliceosome, pointing to the potential involvement of splicing regulation in CLL pathogenesis and chemorefractoriness.

Methods

Patients

The study population comprised 3 cohorts representative of different disease phases: (1) fludarabine-refractory CLL ($n = 59$), including cases ($n = 11$) subjected to whole-exome sequencing (supplemental Table 1, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article); (2) a consecutive series of newly diagnosed and previously untreated patients with CLL ($n = 301$; supplemental Table 2); and (3) clonally related RS ($n = 33$; all diffuse large B-cell lymphomas;

Submitted August 11, 2011; accepted October 18, 2011. Prepublished online as *Blood* First Edition paper, October 28, 2011; DOI 10.1182/blood-2011-08-373159.

*D.R. and A.B. contributed equally to this study.

†R.F., R.D.-F., and G.G. contributed equally to this study.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2011 by The American Society of Hematology

supplemental Table 3). Diagnosis of CLL and of fludarabine-refractoriness were based on International Workshop on CLL–National Cancer Institute (IWCLL–NCI) criteria²; RS was based on histologic criteria.^{1,9}

Peripheral blood tumor samples were obtained as follows: (1) for patients with fludarabine-refractory CLL, immediately before starting treatment to which the patient did not respond because of stable/progressive disease; and (2) for newly diagnosed and previously untreated CLL, at disease presentation. All studies on RS were performed on RS diagnostic biopsies. Germline DNA samples from the same patients were obtained from saliva or from purified granulocytes and confirmed to be tumor-free by PCR of tumor-specific *IGHV-D-J* rearrangements. Patients provided informed consent in accordance with local institutional review board requirements and the Declaration of Helsinki. The study was approved by the ethical committee of the Ospedale Maggiore della Carità di Novara associated with the Amedeo Avogadro University of Eastern Piedmont (protocol code 59/CE; study number CE 8/11).

Mutation analysis of *SF3B1*

Mutation analysis of *SF3B1* (exons 1–25, including splice sites; RefSeq NM_012433.2) was performed on PCR amplicons obtained from genomic DNA by a combination of Sanger sequencing (ABI PRISM 3100 Genetic Analyzer; Applied Biosystems) and targeted next generation sequencing (Genome Sequencer Junior, 454 Life Sciences; Roche; mean coverage approximately 200×). Additional details of sequencing strategies are in supplemental Methods.

FISH karyotype; mutation analysis of *IGHV*, *TP53*, and *NOTCH1*; copy number analysis; and gene expression profile analysis

FISH analysis was performed with the use of probes LSI13 and LSID13S319, CEP12, LSIp53, and LSIATM (Abbott).³ *IGHV* sequences were aligned to ImMunoGeneTics directory and considered mutated if their identity to corresponding germline genes was < 98%.³ *TP53* and *NOTCH1* mutations were analyzed by Sanger sequencing.^{3,7} Genome-wide DNA profiles were obtained with the Affymetrix Genome-Wide Human SNP Array 6.0. Gene expression profile analysis was performed with the use of Affymetrix HG-U133Plus2 arrays. Further details are reported in supplemental Methods.

Statistical analysis

Overall survival was measured from date of diagnosis to date of death (event) or last follow-up (censoring). Treatment-free survival was measured from date of diagnosis to date of progression to symptomatic disease requiring treatment according to IWCLL–NCI guidelines (event),² death, or last follow-up (censoring). Further details are reported in supplemental Methods.

Results and discussion

After the initial observation of recurrent *SF3B1* mutations in 3 of 11 fludarabine-refractory CLL analyzed by whole-exome sequencing, we performed targeted resequencing of the *SF3B1* coding sequence and splice sites in 48 additional cases of progressive and fludarabine-refractory CLL (total number of cases analyzed: 59; supplemental Table 1). *SF3B1* was altered in 10 of 59 (17%) fludarabine-refractory CLL by missense mutations ($n = 9$) or in-frame deletions ($n = 1$) clustering in the HEAT3, HEAT4, and HEAT5 repeats of the *SF3B1* protein (Figures 1 and 2A; supplemental Table 4). Two sites that are highly conserved interspecies (codon 662 and codon 700) were recurrently mutated in 3 and 5 cases, respectively (Figure 1). *SF3B1* mutations were monoallelic and were predicted to be functionally significant according to the PolyPhen-2 algorithm (supplemental Table 4).¹⁰ These data document that mutations of *SF3B1*, a splicing factor that is a critical component of the spliceosome, recurrently associate with fludarabine-refractory CLL.

The biologic characteristics of fludarabine-refractory CLL harboring *SF3B1* mutations are summarized in supplemental Table 1. Mutations occurred irrespective of the *IGHV* mutation status, CD38 expression, and ZAP70 expression. At the time of fludarabine-refractoriness, *SF3B1* mutations were enriched in cases harboring a normal FISH karyotype ($P = .008$; supplemental Table 1). In addition, *SF3B1* mutations distributed in a mutually exclusive fashion compared with *TP53* disruption tested by deletion and/or mutation (mutual information $I = 0.0609$; $P = .046$; Figure 2B). By combining *SF3B1* mutations with other genetic lesions enriched in chemorefractory cases (*TP53* disruption, *NOTCH1* mutations, *ATM* deletion),^{7,11–13} fludarabine-refractory CLL appeared to be characterized by multiple molecular alterations that, to some extent, are mutually exclusive (Figure 2B).

To investigate whether *SF3B1* mutations are restricted to chemorefractory cases, we then compared the prevalence of mutations observed at the time of fludarabine-refractoriness to the prevalence of mutations observed in other disease phases. In a consecutive series evaluated at CLL diagnosis, *SF3B1* mutations were rare (17/301; 5%; Figure 2A; supplemental Table 4) and occurred irrespective of other molecular and immunogenetic features (supplemental Table 2; supplemental Table 5; supplemental Figure 1). Remarkably, 5 of 17 (29%) CLL mutated at diagnosis were primary fludarabine-refractory patients. In these 5 cases, *TP53* disruption and *NOTCH1* mutations occurred in 1 case each. None of the 12 remaining cases harbored *TP53* disruption or *NOTCH1* mutations. By univariate analysis, *SF3B1* mutations showed a crude association with short treatment-free survival ($P < .001$) and overall survival ($P = .011$; Figure 2C). By multivariate analysis, the increased risk of death predicted by *SF3B1* mutations was independent (hazard ratio 3.02; 95% confidence interval 1.24–7.35; $P = .015$) of confounding clinical and biologic variables (supplemental Table 6). Confirmation within the frame of prospective clinical trials will be helpful to fully assess the generalization of *SF3B1* mutations as a CLL prognostic marker.

In CLL investigated at diagnosis, the hotspot distribution and molecular spectrum of *SF3B1* mutations, as well as their mutual relationship with other genetic lesions, were similar to those observed in fludarabine-refractory CLL (Figures 1 and 2B; supplemental Table 4). *SF3B1* mutations were only found in 2 of 33 (6%) clonally related RS (Figures 1 and 2A; supplemental Table 4). Across the different disease phases investigated, mutations were confirmed to be somatically acquired in all cases ($n = 18$) for which germline DNA was available (supplemental Table 4). Among the 3 *SF3B1* mutated cases for which serial samples were analyzed, *SF3B1* mutations were acquired in 2 cases. One fludarabine-refractory CLL (case 7915 in supplemental Table 4) acquired the c.2044A > G p.K666E mutation at the time of refractoriness, and one RS (case 7509 in supplemental Table 4) acquired the c.2146A > G p.K700E mutation at the time of transformation. In the remaining case (case 8343 in supplemental Table 4), the *SF3B1* mutation was present in all disease phases.

Although the relative expression of *SF3B1* in CLL was greater compared with normal B-cell subsets (Figure 2D), extensive investigation by single-nucleotide polymorphism array analysis ruled out focal copy number abnormalities of *SF3B1* in this leukemia ($n = 0/323$). *SF3B1* mutations were consistently absent among mature B-cell neoplasms ($n = 136$) other than CLL (supplemental Table 7). These data document that *SF3B1* mutations: (1) are specific for CLL among mature B-cell neoplasms; (2) occur at a low rate at CLL presentation, whereas they are enriched in fludarabine-refractory cases; and (3) play a minor role in RS transformation, corroborating the notion




Figure 1. *SF3B1* mutations in CLL and RS. Schematic diagram of the human *SF3B1* gene (top) and protein (bottom) with its functional domains (PPP1R8 binding domain and HEAT repeats), and multiple alignment of the HEAT3, HEAT4, and HEAT5 amino acid sequences of the human *SF3B1* protein with orthologous *SF3B1* proteins (n = 15). Amino acids conserved among species are highlighted. Color-coded shapes indicate the position of the mutations found in CLL at diagnosis, in fludarabine-refractory CLL, and in RS.

that CLL histologic shift is molecularly distinct from chemorefractory progression without RS transformation.³

Our identification of *SF3B1* mutations in CLL, and the recent discovery of *SF3B1* mutations in myelodysplasia, points to the involvement of splicing regulation as a novel pathogenetic mechanism in hematologic malignancies.^{14,15} *SF3B1* is a critical component of both major (U2-like) and minor (U12-like) spliceosomes,¹⁶⁻¹⁸ which enact the precise excision of introns from pre-mRNA.¹⁹⁻²¹ The precise biologic role of *SF3B1* mutations in CLL is currently elusive and will require dedicated studies. The pathogenicity of *SF3B1* mutations in CLL is strongly supported by the clustering of these mutations in evolutionarily conserved hotspots localized within HEAT domains, which are tandemly arranged curlicue-like structures serving as flexible scaffolding on which other components can assemble.^{22,23} In addition, the observation that *SF3B1* regulates the alternative splicing program of genes controlling cell-cycle progression and apoptosis points to a potential contribution of *SF3B1* mutations in modulating tumor cell proliferation and survival.^{20,24,25} In addition to pathogenetic implications, *SF3B1* mutations might also provide a therapeutic target for *SF3B1* inhibitors,^{24,25} which are currently under preclinical development as anticancer drugs.

Acknowledgments

This study was supported by grants from AIRC, Special Program Molecular Clinical Oncology, 5 x 1000, No. 10007, Milan, Italy (to

G.G. and R.F.); Progetto FIRB-Programma “Futuro in Ricerca” 2008 (to D.R.), PRIN 2008 (to G.G.), and PRIN 2009 (to D.R.), MIUR, Rome, Italy; Progetto Giovani Ricercatori 2008 (to D.R.) and Ricerca Sanitaria Finalizzata 2008 (to G.G.), Ministero della Salute, Rome, Italy; Compagnia di San Paolo, Turin, Italy (to R.F.); NIH Grant PO1-CA092625 and a Specialized Center of Research grant from the Leukemia & Lymphoma Society (both to R.D.-F.); and Helmut Horten Foundation and San Salvatore Foundation (to F.B.). S.M. and S. Cresta are being supported by fellowships from Novara-AIL Onlus, Novara.

Authorship

Contribution: D.R., L.P., R.F., R.D.-F., and G.G. designed the study, interpreted data, and wrote the manuscript; A.B., V.S., S.R., M.M., S.M., M.C., S. Cresta, and E.G. performed and interpreted mutational analysis; C.D. performed and interpreted FISH studies; H.K. and R.R. performed and interpreted bioinformatics studies; T.V. and S.D. contributed to molecular data analysis and interpretation; M.F., S. Chiaretti, A.G., I.D.G., and F.F. provided well-characterized clinical samples; V.G. performed immunophenotypic studies; and F.B. and L.P. interpreted SNP array data.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Riccardo Dalla-Favera, MD, Institute for Cancer Genetics and the Herbert Irving Comprehensive Cancer




Figure 2. Prevalence, mutual relationship with other genetic lesions, and clinical impact of *SF3B1* mutations in CLL. (A) Prevalence of *SF3B1* mutations in CLL at diagnosis, in fludarabine-refractory CLL, and in RS; numbers on top indicate the actual number of mutated samples over the total number analyzed. (B) Mutual relationship of *SF3B1* mutations with other genetic lesions in CLL at diagnosis and in fludarabine-refractory CLL. In the heat map, rows correspond to identical genes, and columns represent individual patients color-coded based on the gene status (white: wild type; red: mutations of *SF3B1*, mutations of *NOTCH1*, mutations and/or deletion of *TP53*, deletion of *ATM*). (C) Kaplan-Meier estimates of treatment-free survival (TFS) and overall survival (OS) from diagnosis in the consecutive series of newly diagnosed and previously untreated CLL ($n = 301$). *SF3B1* wild-type (*SF3B1* wt) are represented by the blue line. *SF3B1* mutated cases (*SF3B1* M) are represented by the red line. (D) Gene expression levels of *BCL6*, *AICDA*, *BCL2*, *IRF4*, and *SF3B1* in normal B-cell subpopulations (Naive; centroblasts, CB; centrocytes, CC; memory) and CLL samples. Relative levels of gene expression are depicted with a color scale: red represents the greatest level of expression and blue represents the lowest level.

Center, Columbia University, St Nicholas Ave, Rm 508, New York, NY 10032; e-mail: rd10@columbia.edu; and Gianluca Gaidano, MD, PhD, Division of Hematology, Department of Clinical and

Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy; e-mail: gaidano@med.unipmn.it.

References

- Müller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. *World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: IARC; 2008:180-182.
- Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute—Working Group 1996 guidelines. *Blood*. 2008; 111(12):5446-5456.
- Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. *Blood*. 2011;117(12):3391-3401.
- Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. *N Engl J Med*. 2005;352(8):804-815.
- Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. *Leukemia*. 2007;21(9):1885-1891.
- Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. *Hematology Am Soc Hematol Educ Program*. 2010;2010:481-488.
- Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of *NOTCH1* mutational activation. *J Exp Med*. 2011;208(7):1389-1401.
- Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature*. 2011;475(7354):101-105.
- Stein H, Warnke RA, Chan WC, Jaffe ES. Diffuse large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. *World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: IARC; 2008:233-237.
- Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods*. 2010;7(4):248-249.
- Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med*. 2000;343(26):1910-1916.
- Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. *Clin Cancer Res*. 2009;15(3):995-1004.
- Zenz T, Häbe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. *Blood*. 2009;114(13):2589-2597.
- Visconte V, Makishima H, Jankowska A, et al. *SF3B1*, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts [published online ahead of print September 2, 2011]. *Leukemia*. doi:10.1038/leu.2011.232.
- Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. *Nature*. 2011;365(15):1384-1395.
- Luke MM, Della Seta F, Di Como CJ, Sugimoto H, Kobayashi R, Arndt KT. The SAP, a new family of proteins, associate and function positively with

- the SIT4 phosphatase. *Mol Cell Biol.* 1996;16(6):2744-2755.
17. Wang C, Chua K, Seghezzi W, Lees E, Gozani O, Reed R. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. *Genes Dev.* 1998;12(10):1409-1414.
 18. Das BK, Xia L, Palandjian L, Gozani O, Chyung Y, Reed R. Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155. *Mol Cell Biol.* 1999;19(10):6796-6802.
 19. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. *Cell.* 2009;136(4):701-718.
 20. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. *Genes Dev.* 2010;24(21):2343-2364.
 21. Ward AJ, Cooper TA. The pathobiology of splicing. *J Pathol.* 2010;220(2):152-163.
 22. Andrade MA, Bork P. HEAT repeats in the Huntington's disease protein. *Nat Genet.* 1995;11(2):115-116.
 23. Andrade MA, Perez-Iratxeta C, Ponting CP. Protein repeats: structures, functions, and evolution. *J Struct Biol.* 2001;134(2-3):117-131.
 24. Kaida D, Motoyoshi H, Tashiro E, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. *Nat Chem Biol.* 2007;3(9):576-583.
 25. Corrionero A, Miñana B, Valcárcel J. Reduced fidelity of branch point recognition and alternative splicing induced by the antitumor drug spliceostatin A. *Genes Dev.* 2011;25(5):445-459.